The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Sanofi Pasteur announced its first doses of the Fluzone portfolio for the 2017-2018 influenza season have been released by the FDA.
read more
BrainStorm Cell Therapeutics has signed agreements with Mass. General Hospital and CPMC to enroll patients in the planned Phase 3 clinical trial of ...
read more
Kitov announced results of a pre-clinical study demonstrating that NT-219, the lead drug candidate of its subsidiary TyrNovo, in combination with ...
read more
DelMar announced the completion of the first site initiation visit at the Dent Neurological Institute for its Phase 3 Study in Temozolomide-Avastin ...
read more
Nektar announced positive topline results from an oral HAP study of NKTR-181, a first-in-class opioid analgesic.
read more
Capricor Therapeutics announced the FDA has granted Rare Pediatric Disease Designation to CAP-1002, a development candidate for the treatment of ...
read more
BiondVax Pharmaceuticals and the UNISEC consortium reported statistically significant positive results from the Phase 2b clinical trial of M-001, ...
read more
Ablynx has entered into a research collaboration and global exclusive licensing agreement with Sanofi initially focused on developing and ...
read more
Churchill announced the NDA for YONSA ultramicrosize tablets has been accepted for filing by the FDA.
read more
Merck and Pfizer announced the CHMP of the EMA has recommended the approval of avelumab as a monotherapy for metastatic Merkel cell carcinoma.
read more
GSK announced today that the FDA has approved a new subcutaneous formulation of Benlysta for the treatment of adult patients with active, autoantibody...
read more
Seattle Genetics announced a clinical collaboration agreement with Genentech for the evaluation of its investigational (ADC) SGN-LIV1A in combination ...
read more
Biohaven Pharmaceutical has commenced enrollment in the first of its two registrational Phase 3 clinical trials to evaluate orally-dosed rimegepant ...
read more
HedgePath announced the FDA has provided further guidance regarding HPPI's ongoing, open-label Phase 2(b) clinical trial studying the effect of SUBA-...
read more
Stealth BioTherapeutics announced the initiation of TAZPOWER, a Phase 2/3 study evaluating elamipretide in patients with Barth syndrome.
read more